• Ertugliflozin Attenuates Tau Hyperphosphorylation via Brain

  2026-07-01

  The reference study demonstrates that ertugliflozin, a sodium glucose co-transporter 2 inhibitor, reverses cognitive deficits and tau hyperphosphorylation in a rat model of Alzheimer’s disease by restoring brain insulin signaling. These findings highlight the role of metabolic modulation in neurodegenerative disease research and provide mechanistic insight into insulin signaling disruption underlying Alzheimer’s pathology.

• Lithium-Induced Exosomal Wnt10a Release Enhances Osteogenesi

  2026-06-30

  This study uncovers a mechanism by which lithium promotes osteogenesis in bone mesenchymal stem cells (BMSCs) through Rab11a-mediated exosomal Wnt10a secretion and subsequent activation of Wnt/β-catenin signaling. The findings clarify how lithium-engineered exosomes can be leveraged to accelerate bone regeneration, offering new strategies for bone repair therapies.

• Ciclesonide and Desisobutyryl-Ciclesonide in Advanced Asthma

  2026-06-30

  Ciclesonide’s rapid prodrug conversion and targeted glucocorticoid receptor activation offer unmatched precision for respiratory disease models and next-generation anti-inflammatory studies. This article details actionable workflows, troubleshooting strategies, and new directions enabled by ERAD-hijacking technologies.

• Targeting Fructose Metabolism in Cancer: Polyol Pathway Insi

  2026-06-29

  The referenced Cancer Letters study synthesizes recent evidence linking upregulated fructose metabolism—and specifically the polyol pathway—to the malignancy of several aggressive cancers. Its thorough analysis of GLUT5, KHK, and aldose reductase upregulation underlines the therapeutic promise of metabolic interventions targeting these pathways.

• ERAD-Engaging Chimeras Enable Targeted Degradation of TM Pro

  2026-06-29

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a novel small-molecule platform that co-opts the ER-associated degradation (ERAD) pathway to enable precise degradation of transmembrane proteins, overcoming key limitations of prior targeted protein degradation approaches. This innovation holds significant promise for drug discovery, particularly in disease contexts where membrane protein modulation is crucial.

• WY-14643 (Pirinixic Acid): Precision PPARα Agonism in Metabo

  2026-06-28

  WY-14643 (Pirinixic Acid) enables translational researchers to unravel PPARα-driven pathways in metabolic and inflammatory diseases, bridging mechanistic insight with actionable protocol strategy. This thought-leadership article situates WY-14643 within the context of emerging environmental triggers of PPARα dysregulation, competitive tool compounds, and high-impact translational workflows—moving beyond product listings to offer a strategic roadmap for metabolic disorder research.

• Ciclesonide and Desisobutyryl-Ciclesonide: Precision for Ast

  2026-06-27

  Harness the dual power of ciclesonide and desisobutyryl-ciclesonide for high-fidelity respiratory disease models and targeted anti-inflammatory workflows. Learn how APExBIO’s robust compound and new ERAD-based methods unlock assay reproducibility and innovation in glucocorticoid receptor research.

• Apicidin: Histone Deacetylase Inhibitor for Advanced Epigene

  2026-06-26

  Apicidin is a highly selective histone deacetylase inhibitor that empowers researchers to dissect chromatin regulation and cellular proliferation mechanisms with precision. Its robust anti-proliferative and anti-angiogenic properties make it indispensable for both cancer and reproductive toxicology studies, especially when rigorous, reproducible assays are required.

• Capsazepine: Precision TRPV1 Ion Channel Antagonist for Pain

  2026-06-26

  Capsazepine is a potent TRPV1 ion channel antagonist with robust efficacy in inhibiting capsaicin-induced nociception and modulating apoptosis sensitization in colon cancer cells. Its unique polypharmacological profile, including TRPM8 and nicotinic receptor inhibition, enables high-precision dissection of pain and cell death pathways. APExBIO's A3279 kit delivers ≥98% pure material for reproducible research.

• Sodium Oxamate in Cancer Metabolism: Protocols & Troubleshoo

  2026-06-25

  Sodium Oxamate empowers cancer researchers to dissect lactate-driven resistance, uncovering new metabolic vulnerabilities in aggressive tumors. This article provides actionable protocols, troubleshooting strategies, and advanced insights, translating the latest findings on histone lactylation into practical assay enhancements.

• MHY1485: Advanced mTOR Activation for Precision Autophagy As

  2026-06-25

  Explore how MHY1485, a potent mTOR activator, enables unprecedented precision in autophagy assay design and metabolic pathway research. Discover critical protocol insights and reference-driven recommendations to advance your cell signaling investigations.

• EdU Imaging Kits (Cy3): Strategic Leverage for S-Phase Disco

  2026-06-24

  This thought-leadership article explores the mechanistic and translational advantages of EdU Imaging Kits (Cy3) for quantifying S-phase DNA synthesis in cell proliferation studies. Integrating evidence from recent kidney development research, real-world protocol parameters, and competitive benchmarking, we offer researchers actionable guidance for advancing both mechanistic discovery and translational application, while expanding the discussion beyond typical product content. The article references the latest findings on Drosha in mesangial cells and situates EdU imaging within the broader landscape of cell proliferation and genotoxicity research.

• Lenalidomide (CC-5013): Optimized Workflows in Myeloma Resea

  2026-06-23

  Lenalidomide (CC-5013) empowers researchers with potent immunomodulatory and anti-angiogenic mechanisms, now further enhanced through epigenetic synergy strategies. This article delivers actionable workflow design, troubleshooting best practices, and advanced use-cases anchored in the latest experimental and clinical evidence.

• EPI-001: Androgen Receptor N-Terminal Domain Inhibitor in On

  2026-06-23

  EPI-001, a pioneering androgen receptor N-terminal domain inhibitor, unlocks new possibilities for targeting resistant prostate and triple-negative breast cancer models. This guide distills evidence-based workflows, troubleshooting insights, and practical protocol enhancements to maximize research outcomes using EPI-001 from APExBIO.

• ALT Cancer Cells and ATR Inhibition: Rethinking Sensitivity

  2026-06-22

  This study rigorously re-examines whether cancer cells using the alternative lengthening of telomeres (ALT) pathway are uniquely sensitive to ATR inhibition. The findings challenge previous assumptions, revealing that ALT status does not confer general hypersensitivity to ATR inhibitors, with implications for targeted cancer therapy design.

454 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page